MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease
- 25 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 63 (9), 1916-1931
- https://doi.org/10.1007/s00125-020-05197-2
Abstract
Aims/hypothesis Myeloid-derived growth factor (MYDGF), mainly secreted by bone marrow-derived cells, has been known to promote glucagon-like peptide-1 production and improve glucose/lipid metabolism in mouse models of diabetes, but little is known about the functions of MYDGF in diabetic kidney disease (DKD). Here, we investigated whether MYDGF can prevent the progression of DKD. Methods In vivo experiments, both loss- and gain-of-function strategies were used to evaluate the effect of MYDGF on albuminuria and pathological glomerular lesions. We used streptozotocin-treated Mydgf knockout and wild-type mice on high fat diets to induce a model of DKD. Then, albuminuria, glomerular lesions and podocyte injury were evaluated in Mydgf knockout and wild-type DKD mice treated with adeno-associated virus-mediated Mydgf gene transfer. In vitro and ex vivo experiments, the expression of slit diaphragm protein nephrin and podocyte apoptosis were evaluated in conditionally immortalised mouse podocytes and isolated glomeruli from non-diabetic wild-type mice treated with recombinant MYDGF. Results MYDGF deficiency caused more severe podocyte injury in DKD mice, including the disruption of slit diaphragm proteins (nephrin and podocin) and an increase in desmin expression and podocyte apoptosis, and subsequently caused more severe glomerular injury and increased albuminuria by 39.6% compared with those of wild-type DKD mice (p < 0.01). Inversely, MYDGF replenishment attenuated podocyte and glomerular injury in both wild-type and Mydgf knockout DKD mice and then decreased albuminuria by 36.7% in wild-type DKD mice (p < 0.01) and 34.9% in Mydgf knockout DKD mice (p < 0.01). Moreover, recombinant MYDGF preserved nephrin expression and inhibited podocyte apoptosis in vitro and ex vivo. Mechanistically, the renoprotection of MYDGF was attributed to the activation of the Akt/Bcl-2-associated death promoter (BAD) pathway. Conclusions/interpretation The study demonstrates that MYDGF protects podocytes from injury and prevents the progression of DKD, providing a novel strategy for the treatment of DKD. Graphical abstractKeywords
Funding Information
- The National Natural Science Foundation of China (NSFC 81870573)
- Research Project of Health Commission of Hubei Province (WJ2017H0031)
- National Key Research and Development Program of China (2016YFC1305601)
This publication has 50 references indexed in Scilit:
- Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuriaKidney International, 2010
- Proteinuria in diabetic kidney disease: A mechanistic viewpointKidney International, 2008
- Podocyte biology in diabetic nephropathyKidney International, 2007
- Glucose-Induced Reactive Oxygen Species Cause Apoptosis of Podocytes and Podocyte Depletion at the Onset of Diabetic NephropathyDiabetes, 2006
- Insulin-like growth factors inhibit podocyte apoptosis through the PI3 kinase pathwayKidney International, 2005
- Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathiesKidney International, 2004
- Phosphatidylinositol 3-Kinase (PI-3K)/Akt but Not PI-3K/p70 S6 Kinase Signaling Mediates IGF-1-Promoted Lens Epithelial Cell SurvivalInvestigative Ophthalmology & Visual Science, 2004
- Lentiviral Gene Transduction of KidneyHuman Gene Therapy, 2002
- Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death MachineryCell, 1997
- Glomerular Filtration Rate and Renal Plasma Flow in Short-term and Long-term Juvenile Diabetes MellitusScandinavian Journal of Clinical and Laboratory Investigation, 1971